Who
Chidozie Ugwumba
10% owner
Company insider
Files Form 4 as: Director and 10% owner and Other, Clene; Director, Carisma Therapeutics; Other, BiomX.
In numbers
- Trades disclosed
- 196
- Buys
- 2
- Sells
- 124
- Bought
- $7.0M
- Sold
- $9.9M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 30 Apr 2021
- Last trade
- 17 Jul 2026
- Last filed
- 6 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jul 2026filed 6 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code J | —375,000 | filing |
| 17 Jul 2026filed 6 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code J | —424,358 | filing |
| 17 Jul 2026filed 6 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code J | —375,000 | filing |
| 17 Jul 2026filed 6 Aug 2026 | CLNN Cleneoption or derivative · Biotechnology | SEC FORM 4 Code J | —424,358 | filing |
| 12 May 2026filed 13 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $454K73,296 at $6.20 | filing |
| 12 May 2026filed 13 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $454K73,296 at $6.20 | filing |
| 11 May 2026filed 13 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $150K22,177 at $6.75 | filing |
| 11 May 2026filed 13 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $150K22,177 at $6.75 | filing |
| 4 May 2026filed 5 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $496K72,884 at $6.80 | filing |
| 4 May 2026filed 5 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $496K72,884 at $6.80 | filing |
| 1 May 2026filed 5 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $35K5,795 at $6.01 | filing |
| 1 May 2026filed 5 May 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $35K5,795 at $6.01 | filing |
| 30 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $35K5,736 at $6.08 | filing |
| 30 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $35K5,736 at $6.08 | filing |
| 29 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $69K12,170 at $5.63 | filing |
| 29 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $69K12,170 at $5.63 | filing |
| 28 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $9,3871,591 at $5.90 | filing |
| 28 Apr 2026filed 30 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $9,3871,591 at $5.90 | filing |
| 21 Apr 2026filed 22 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $377K61,345 at $6.14 | filing |
| 21 Apr 2026filed 22 Apr 2026 | CLNN CleneBiotechnology | SEC FORM 4 Sold | $377K61,345 at $6.14 | filing |
News
Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSCLNN · manilatimes.net · 19 Oct 2026Head to Head Survey: Shineco (NASDAQ:SISI) vs. Clene (NASDAQ:CLNN)CLNN · tickerreport.com · 8 Oct 2026
0 headlines in the last 90 days name Chidozie Ugwumba; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.